tbResList Print — ATV Atorvastatin

Filters: qv=2, qv2=%, rfv=%

Product

ATV Atorvastatin
Features: Statin
Description: <b>Atorvastatin</b> is a statin, i.e., an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Clinically it is prescribed to lower LDL cholesterol and cardiovascular risk.<br>

<pre>
Across preclinical and observational contexts, atorvastatin tends to:
-DOWNREGULATE proliferative and survival signaling (via impaired prenylation)
-REDUCE inflammatory signaling (NF-κB–linked effects)
-MODULATE immune and stromal interactions
-SENSITIZE some tumors to chemotherapy or radiation (context-dependent)
</pre>
-Epidemiologic studies suggest statin use is associated with reduced incidence or improved outcomes in some cancers (e.g., colorectal, prostate, breast).<br>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress

ROS↑, 1,  

Core Metabolism/Glycolysis

Histones↝, 1,   HMG-CoA↓, 7,   LDL↓, 1,   SREBP2↓, 2,   SREBP2↑, 1,  

Cell Death

Apoptosis↑, 4,  

Transcription & Epigenetics

ac‑H3↑, 1,   ac‑H4↑, 1,   other↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

Proliferation, Differentiation & Cell State

HDAC↓, 1,   HMGCR↑, 1,   HMGCR⇅, 1,   HMGCR↓, 1,   TumCG↓, 2,  

Migration

AntiAg↑, 2,   TumCMig↓, 1,   TumCP↓, 2,  

Barriers & Transport

P-gp↓, 1,  

Immune & Inflammatory Signaling

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance

BioEnh↑, 1,   ChemoSen↑, 1,   eff↑, 5,   P450↓, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes

AntiTum↓, 1,   OS↑, 1,   PDE4↓, 1,   radioP↑, 2,  
Total Targets: 36

Pathway results for Effect on Normal Cells

Cell Death

Akt↑, 1,  

Angiogenesis & Vasculature

eNOS↑, 1,  

Functional Outcomes

cardioP↑, 2,   toxicity↓, 1,  
Total Targets: 4

Research papers

Year Title Authors PMID Link Flag
2025Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancerJuliane M. Libertohttps://aacrjournals.org/cancerres/article/85/8_Supplement_1/2214/756240/Abstract-2214-Inhibiting-the-mevalonate-pathway0
2024Short‐Term Statin Treatment Reduces, and Long‐Term Statin Treatment Abolishes, Chronic Vascular Injury by Radiation TherapyKarima Ait‐Aissa,https://www.ahajournals.org/doi/full/10.1161/JAHA.123.0335580
2024Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell LinesNanami IriePMC10968169https://pmc.ncbi.nlm.nih.gov/articles/PMC10968169/0
2024Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell LinesNanami IriePMC10968169https://pmc.ncbi.nlm.nih.gov/articles/PMC10968169/0
2023A review of effects of atorvastatin in cancer therapyZahra Shaghaghihttps://link.springer.com/article/10.1007/s12032-022-01892-90
2021Crosstalk between Statins and Cancer Prevention and Therapy: An UpdateBeniamin Oskar GrabarekPMC8704600https://pmc.ncbi.nlm.nih.gov/articles/PMC8704600/0
2020Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing RadiationSeyed Jalal HosseinimehrPMC7667559https://pmc.ncbi.nlm.nih.gov/articles/PMC7667559/0
2011The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancerAleksandra Pandyrahttps://aacrjournals.org/mct/article/10/11_Supplement/C170/238614/Abstract-C170-The-combination-of-statins-and0
2014Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than oneAleksandra PandyraPMC4905210https://pmc.ncbi.nlm.nih.gov/articles/PMC4905210/0
2014Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback LoopAleksandra Pandyrahttps://aacrjournals.org/cancerres/article/74/17/4772/593281/Immediate-Utility-of-Two-Approved-Agents-to-Target0
2007Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combinationYumei Ye17416607https://pubmed.ncbi.nlm.nih.gov/17416607/0
2019Bioenhancing effects of naringin on atorvastatinVenkatesh SamaPMC8957237https://pmc.ncbi.nlm.nih.gov/articles/PMC8957237/0